CT 03 programme - Captor Therapeutics
Alternative Names: CT-03; CT-03 degraders; CT-03 projectLatest Information Update: 17 Dec 2022
At a glance
- Originator Captor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 26 Oct 2022 Pharmacodynamics data from preclinical trial in Haematological malignancies presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)
- 25 Jan 2022 CT 03 is available for licensing as of 13 Jan 2022. http://www.captortherapeutics.com/our-approach
- 20 Jan 2022 Captor Therapeutics plans to submit IND application for CT 03 degraders